Robert Orr
InvestorCo-Founder & Managing Partner F-LOG Ventures at F-LOG Ventures · Managing Partner at XPRESS Ventures · CEO and Managing Partner, Cuna del Mar LP at Natural Products Canada
Toronto, Ontario, Canada
Find your path to Robert
35 people in our graph share verified history with Robert — schools, employers, funds. One of them is your warm intro.
About
Robert Orr runs a specialized consulting firm and serves as CEO and managing partner of Cuna del Mar LP, a US-based private equity fund focused on environmentally sustainable aquaculture and global food security. From 1996 to 2011 he was co-founder, CEO and president of Ocean Nutrition Canada, an omega-3 fish oil supplier that was sold to Royal DSM N.V. in 2012. He co-founded and chaired industry groups including the CRN omega-3 working group and the Global Omega-3 Trade Association (GOED), and his career spans over 35 years in private equity, marine biotech, and nutritional ingredients.
Invests in
AgTechBiotechFoodTech
Investments
Board seats
ABK BiomedicalSlanmhor Pharmaceuticals Inc.
Per the firm's website.
Colleagues at F-LOG Ventures
Frequently asked questions
- Who is Robert Orr?
- Robert Orr runs a specialized consulting firm and serves as CEO and managing partner of Cuna del Mar LP, a US-based private equity fund focused on environmentally sustainable aquaculture and global food security. From 1996 to 2011 he was co-founder, CEO and president of Ocean Nutrition Canada, an omega-3 fish oil supplier that was sold to Royal DSM N.V. in 2012. He co-founded and chaired industry groups including the CRN omega-3 working group and the Global Omega-3 Trade Association (GOED), and his career spans over 35 years in private equity, marine biotech, and nutritional ingredients.
- Where does Robert Orr work?
- Robert Orr is Co-Founder & Managing Partner F-LOG Ventures at F-LOG Ventures.
- What does Robert Orr invest in?
- Robert Orr invests in AgTech, Biotech, FoodTech.
- What boards does Robert Orr sit on?
- Robert Orr holds tracked board seats at ABK Biomedical, Slanmhor Pharmaceuticals Inc..